Science Explorer Back to mapMap
Discussion
Researcher · Apexigen (United States) · United States

Erin L. Filbert

Erin L. Filbert publishes mostly in Immunology, Oncology and Molecular Biology, on topics such as Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers and Monoclonal and Polyclonal Antibodies Research.

ORCID 0000-0001-5077-9030 OpenAlex
World rank
#2,096,525
of 7,710,434 ranked researchers
Rank in United States
#632,947
of 1,627,098
Works
63
Citations
702
Citations per work
11.1
h-index
8
i10-index 7Top 85% in Immunology
Erin L. Filbert

What does Erin L. Filbert research?

Erin L. Filbert's work is mostly in Immunology and Microbiology (41%), Medicine (25%), Biochemistry, Genetics and Molecular Biology (15%).

Life Sciences: 35 works · 56.0% of their workImmunology and Microbiology: 26 works · 41.3% of their workImmunology: 26 works · 41.3% of their workBiochemistry, Genetics and Molecular Biology: 9 works · 14.7% of their workMolecular Biology: 8 works · 12.0% of their workCell Biology: 2 works · 2.7% of their workHealth Sciences: 16 works · 25.3% of their workMedicine: 16 works · 25.3% of their workOncology: 8 works · 13.3% of their workRadiology, Nuclear Medicine and Imaging: 6 works · 9.3% of their workNephrology: 2 works · 2.7% of their workEverything else: 12 works · 18.7% of their workTHEIR WORKErin L. Filbert63works
Life Sciences56%Health Sciences25%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Immunology and Microbiology2641.3%
    2. Biochemistry, Genetics and Molecular Biology914.7%
    1. Medicine1625.3%
  3. Everything else1218.7%
  1. 1Immunology41% of their works
  2. 2Oncology13% of their works
  3. 3Molecular Biology12% of their works
  4. 4Radiology, Nuclear Medicine and Imaging9% of their works
  5. 5Nephrology3% of their works
  6. 6Cell Biology3% of their works

Research topics

Which keywords describe Erin L. Filbert's research?

The keywords of their largest research topics: Immunity, Cancer Immunotherapy, Dendritic Cells, Fc Receptors, Immune Checkpoint Blockade, PD-1 and PD-L1, Therapeutic Antibodies and Activation.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 17 words, with their numbers
  1. Immunity152 topics
  2. Cancer Immunotherapy111 topic
  3. Dendritic Cells111 topic
  4. Fc Receptors61 topic
  5. Immune Checkpoint Blockade61 topic
  6. PD-1 and PD-L161 topic
  7. Therapeutic Antibodies61 topic
  8. Activation41 topic
  9. BRAF gene41 topic
  10. Foxp341 topic
  11. MAP Kinase41 topic
  12. Macrophage41 topic
  13. NK Cell Recognition41 topic
  14. Natural Killer Cells41 topic
  15. TGF-ß41 topic
  16. Genetic Mutations31 topic
  17. Primary Immunodeficiency31 topic

Where does Erin L. Filbert work?

Erin L. Filbert's main affiliation in the publication record is Apexigen (United States), United States.

How many publications and citations does Erin L. Filbert have?

OpenAlex counts 63 works and 702 citations for Erin L. Filbert, an h-index of 8, ranking #2,096,525 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Erin L. Filbert. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.